Antoniou Tony, Macdonald Erin M, Hollands Simon, Gomes Tara, Mamdani Muhammad M, Garg Amit X, Paterson J Michael, Juurlink David N
Department of Family and Community Medicine, St. Michael's Hospital, Toronto, Ont. ; Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Ont. ; Institute for Clinical Evaluative Sciences, Toronto, Ont.
Institute for Clinical Evaluative Sciences, Toronto, Ont.
CMAJ Open. 2015 Apr 2;3(2):E166-71. doi: 10.9778/cmajo.20140074. eCollection 2015 Apr-Jun.
Proton pump inhibitors (PPIs) cause interstitial nephritis and are an underappreciated cause of acute kidney injury. We examined the risk of acute kidney injury and acute interstitial nephritis in a large population of older patients receiving PPIs.
We conducted a population-based study involving Ontario residents aged 66 years and older who initiated PPI therapy between Apr. 1, 2002, and Nov. 30, 2011. We used propensity score matching to establish a highly comparable reference group of control patients. The primary outcome was hospital admission with acute kidney injury within 120 days, and a secondary analysis examined acute interstitial nephritis. We used Cox proportional hazards regression to adjust for differences between groups.
We studied 290 592 individuals who commenced PPI therapy and an equal number of matched controls. The rates of acute kidney injury (13.49 v. 5.46 per 1000 person-years, respectively; hazard ratio [HR] 2.52, 95% CI 2.27 to 2.79) and acute interstitial nephritis (0.32 vs. 0.11 per 1000 person-years; HR 3.00, 95% CI 1.47 to 6.14) were higher among patients given PPIs than among controls.
In our study population of older adults, those who started PPI therapy had an increased risk of acute kidney injury and acute interstitial nephritis. These are potentially reversible conditions that may not be readily attributed to drug treatment. Clinicians should appreciate the risk of acute interstitial nephritis during treatment with PPIs, monitor patients appropriately and discourage the indiscriminate use of these drugs.
质子泵抑制剂(PPIs)可导致间质性肾炎,是急性肾损伤的一个未得到充分认识的病因。我们在大量接受PPIs治疗的老年患者中研究了急性肾损伤和急性间质性肾炎的风险。
我们进行了一项基于人群的研究,纳入了2002年4月1日至2011年11月30日期间开始PPI治疗的安大略省66岁及以上居民。我们使用倾向评分匹配来建立一个高度可比的对照患者参考组。主要结局是在120天内因急性肾损伤住院,次要分析则研究急性间质性肾炎。我们使用Cox比例风险回归来调整组间差异。
我们研究了290592名开始PPI治疗的个体以及数量相等的匹配对照。PPIs治疗组患者的急性肾损伤发生率(分别为每1000人年13.49例和5.46例;风险比[HR]2.52,95%CI 2.27至2.79)和急性间质性肾炎发生率(每1000人年0.32例对0.11例;HR 3.00,95%CI 1.47至6.14)高于对照组。
在我们的老年研究人群中,开始PPI治疗的患者发生急性肾损伤和急性间质性肾炎的风险增加。这些情况可能是可逆的,可能不容易归因于药物治疗。临床医生应认识到PPIs治疗期间急性间质性肾炎的风险,对患者进行适当监测,并避免这些药物的滥用。